These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38206946)

  • 1. Latent and active tuberculosis development in patients with rheumatoid arthritis receiving biologic disease-modifying antirheumatic drugs: A single-center prospective study.
    Hai BB; Anh TL; Thi Thu PN; Van HN; Van GV; Van DH
    PLoS One; 2024; 19(1):e0295048. PubMed ID: 38206946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.
    Song YJ; Cho SK; Kim H; Kim HW; Nam E; Bae SC; Yoo DH; Sung YK
    J Korean Med Sci; 2021 Mar; 36(10):e70. PubMed ID: 33724737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests.
    Malaviya AN; Aggarwal VK; Rawat R; Baghel S; Thakran R; Zaheer Q; Garg S; Kapoor S
    Int J Rheum Dis; 2018 Aug; 21(8):1563-1571. PubMed ID: 29345081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden.
    Shin A; Lee YJ; Lee EB; Song YW; Kim SC; Kang EH
    Rheumatology (Oxford); 2021 Jun; 60(6):2755-2764. PubMed ID: 33188421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis in Biologic-naïve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis Characteristics.
    Sundbaum JK; Arkema EV; Bruchfeld J; Jonsson J; Askling J; Baecklund E
    J Rheumatol; 2021 Aug; 48(8):1243-1250. PubMed ID: 33795331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis.
    Cuomo G; D’Abrosca V; Iacono D; Pantano I
    Clin Rheumatol; 2017 Feb; 36(2):457-461. PubMed ID: 27817127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Neopterin Levels Are Associated with Increased Tuberculosis Risk in Rheumatoid Arthritis Patients with QuantiFERON Conversion during Biologic Therapy.
    Chen DY; Li JP; Chen YM; Liao TL; Chen HH; Hsieh CW; Yeh YW; Lan JL
    PLoS One; 2016; 11(11):e0166301. PubMed ID: 27861525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.
    Cantini F; Nannini C; Niccoli L; Iannone F; Delogu G; Garlaschi G; Sanduzzi A; Matucci A; Prignano F; Conversano M; Goletti D;
    Autoimmun Rev; 2015 Jun; 14(6):503-9. PubMed ID: 25617816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?
    Ozsoy Z; Ozdemir A; Ekici M; Bilgin E; Kılıc L; Kiraz S; Sarıbas Z; Sener B; Karadag O
    Rheumatol Int; 2023 Aug; 43(8):1445-1451. PubMed ID: 37005937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a commercial interferon-gamma release assay and tuberculin skin test for the detection of latent tuberculosis infection in Hong Kong arthritis patients who are candidates for biologic agents.
    So H; Yuen CS; Yip RM
    Hong Kong Med J; 2017 Jun; 23(3):246-50. PubMed ID: 28126971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018.
    Jung SM; Han M; Kim EH; Jung I; Park YB
    Arthritis Res Ther; 2022 Jun; 24(1):157. PubMed ID: 35761359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients.
    Wang PH; Lin CH; Chang TH; Wu CS
    BMC Pulm Med; 2020 Aug; 20(1):232. PubMed ID: 32867745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review.
    Lima LM; Aurilio RB; Fonseca AR; Parente AAAI; Sant'Anna MFBP; Sant'Anna CC
    Rev Paul Pediatr; 2023; 42():e2022084. PubMed ID: 37436237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
    Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
    Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registry.
    Oulkadi L; Rostom S; Hmamouchi I; El Hassani Sbai S; El Binoune I; Amine B; Abouqal R; Allali F; Achemlal L; El Bouchti I; El Maghraoui A; Ghozlani I; Hassikou H; Harzy T; Ichchou L; Mkinsi O; Niamane R; Bahiri R
    Rheumatol Int; 2021 Sep; 41(9):1625-1631. PubMed ID: 34173843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy.
    Chen DY; Shen GH; Hsieh TY; Hsieh CW; Lan JL
    Arthritis Rheum; 2008 Jun; 59(6):800-6. PubMed ID: 18512714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.